• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapy and medication do not work for many people suffering from depression. The individual approach to treatment could be the answer.

Cue is an intervention platform for digital devices that translates passively acquired normal smartphone sensor data into personalized micro-interventions designed to improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to discover their predictors of feature and reveal distinct features that are able to change mood as time passes.

Predictors of Mood

Depression is among the leading causes of mental illness.1 Yet, only half of those suffering from the condition receive treatment1. In order to improve outcomes, clinicians need to be able to recognize and treat patients who have the highest likelihood of responding to particular treatments.

Personalized depression treatment is one way to do this. By using mobile phone sensors as well as an artificial intelligence voice assistant and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from which treatments. With two grants awarded totaling over $10 million, they will make use of these techniques to determine the biological and behavioral factors that determine the response to antidepressant medication and psychotherapy.

The majority of research done to so far has focused on sociodemographic and clinical characteristics. These include demographic variables like age, sex and education, clinical characteristics including symptom severity and comorbidities, and biological markers such as neuroimaging and genetic variation.

While many of these factors can be predicted by the information in medical records, only a few studies have utilized longitudinal data to determine the factors that influence mood in people. Few studies also consider the fact that moods can be very different between individuals. Therefore, it is crucial to develop methods that allow for the determination of individual differences in mood predictors and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to identify patterns of behaviour and emotions that are unique to each person.

In addition to these methods, the team created a machine learning algorithm to model the dynamic factors that determine a person's depressed mood. The algorithm combines these personal variations into a distinct "digital phenotype" for each participant.

This digital phenotype was correlated with CAT DI scores, a psychometrically validated scale for assessing severity of symptom. However, the correlation was weak (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 x 10-03) and varied widely among individuals.

Predictors of Symptoms

Depression is among the world's leading causes of disability1 but is often underdiagnosed and undertreated2. Depressive disorders are often not treated due to the stigma associated with them and the absence of effective interventions.

To assist in individualized treatment, it is important to determine the predictors of symptoms. However, the current methods for predicting symptoms rely on clinical interview, which has poor reliability and only detects a limited number of symptoms that are associated with depression.2

Machine learning can increase the accuracy of the diagnosis and treatment for depression and anxiety of depression by combining continuous digital behavior phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can provide continuous, high-resolution measurements as well as capture a wide variety of distinctive behaviors and activity patterns that are difficult to document through interviews.

The study involved University of California Los Angeles (UCLA) students with mild to severe depression treatment near me symptoms. enrolled in the Screening and treatment resistant depression for Anxiety and Depression (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were referred to online support or in-person clinical treatment depending on their depression treatment medications treatment tms (https://wayranks.com/author/penroast45-730536) severity. Those with a CAT-DI score of 35 or 65 were allocated online support via a peer coach, while those with a score of 75 patients were referred to clinics in-person for psychotherapy.

Participants were asked a series questions at the beginning of the study regarding their demographics and psychosocial characteristics. These included age, sex, education, work, and financial status; if they were partnered, divorced or single; their current suicidal ideas, intent or attempts; as well as the frequency at which they drank alcohol. The CAT-DI was used to assess the severity of depression symptoms on a scale from 100 to. The CAT-DI assessment was carried out every two weeks for participants who received online support and weekly for those who received in-person care.

Predictors of Treatment Reaction

Research is focusing on personalization of depression treatment. Many studies are aimed at finding predictors that can help doctors determine the most effective medications to treat each individual. Pharmacogenetics in particular identifies genetic variations that determine how the human body metabolizes drugs. This allows doctors select medications that are most likely to work for each patient, reducing the time and effort needed for trial-and error treatments and eliminating any adverse negative effects.

Another promising approach is building models of prediction using a variety of data sources, including data from clinical studies and neural imaging data. These models can be used to identify the best combination of variables that are predictive of a particular outcome, like whether or not a particular medication is likely to improve mood and symptoms. These models can be used to determine the response of a patient to treatment, allowing doctors to maximize the effectiveness.

A new generation of machines employs machine learning methods such as supervised and classification algorithms such as regularized logistic regression, and tree-based methods to combine the effects from multiple variables and improve predictive accuracy. These models have shown to be effective in the prediction of treatment outcomes like the response to antidepressants. These models are getting more popular in psychiatry, and it is likely that they will become the norm for the future of clinical practice.

In addition to ML-based prediction models research into the mechanisms behind depression is continuing. Recent research suggests that the disorder is linked with neural dysfunctions that affect specific circuits. This theory suggests that a individualized treatment for depression will be based on targeted therapies that restore normal function to these circuits.

Internet-based-based therapies can be a way to achieve this. They can provide a more tailored and individualized experience for patients. One study found that an internet-based program improved symptoms and provided a better quality life for MDD patients. A randomized controlled study of a personalized treatment for depression found that a significant percentage of patients experienced sustained improvement and had fewer adverse negative effects.

Predictors of adverse effects

In the treatment of depression, a major challenge is predicting and identifying which antidepressant medications will have very little or no side negative effects. Many patients are prescribed a variety of medications before settling on a treatment that is effective and tolerated. Pharmacogenetics is an exciting new way to take an effective and precise approach to choosing antidepressant medications.

Many predictors can be used to determine which antidepressant is best to prescribe, such as gene variations, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and comorbidities. To determine the most effective treatment for depression reliable and accurate predictors for a specific treatment, randomized controlled trials with larger numbers of participants will be required. This is because the detection of interaction effects or moderators may be much more difficult in trials that consider a single episode of treatment per patient instead of multiple episodes of treatment over a period of time.

Additionally, predicting a patient's response will likely require information on the comorbidities, symptoms profiles and the patient's subjective experience of tolerability and effectiveness. At present, only a few easily identifiable sociodemographic and clinical variables seem to be correlated with response to MDD factors, including age, gender race/ethnicity, SES BMI and the presence of alexithymia, and the severity of depression symptoms.

The application of pharmacogenetics to depression treatment is still in its beginning stages, and many challenges remain. First, a clear understanding of the underlying genetic mechanisms is essential as well as a clear definition of what is a reliable predictor of treatment response. In addition, ethical issues like privacy and the ethical use of personal genetic information should be considered with care. In the long term the use of pharmacogenetics could provide an opportunity to reduce the stigma that surrounds mental health care and improve the outcomes of those suffering with depression. But, like any other psychiatric treatment, careful consideration and implementation is required. For now, the best method is to offer patients a variety of effective medications for depression and encourage them to speak openly with their doctors about their concerns and experiences.